Immunology

Jack (John) McGinty, Ph.D. is a research scientist at 2seventy Bio, a biotech company making cutting-edge immunotherapies for the treatment of cancer. His current work focuses on the development of CAR T cell therapy. In this process patient T cells are isolated, genetically reprogrammed, and injected into the body where they detect and kill cancer cells. Dr. McGinty holds a Ph.D. in Immunology from the University of Washington, where he studied host immune responses to parasite infection, as well as a B.S. in Microbiology from Ohio University.

Jack (John) McGinty, Ph.D. is a research scientist at 2seventy Bio, a biotech company making cutting-edge immunotherapies for the treatment of cancer. His current work focuses on the development of CAR T cell therapy. In this process patient T cells are isolated, genetically reprogrammed, and injected into the body where they detect and kill cancer cells. Dr. McGinty holds a Ph.D. in Immunology from the University of Washington, where he studied host immune responses to parasite infection, as well as a B.S. in Microbiology from Ohio University.

Ejae Goddard (they/them) has a background in cancer, metastasis, immunology, and T cell-based immunotherapies. They received a B.S. in Microbiology from the University of Kansas in 2004. During this time they gained experience in a research lab studying herpesviruses. They went on to earn a PhD in Cancer Research from Oregon Health and Sciences University in 2017 while working in the lab of Dr. Pepper Schedin. Ejae's PhD work focused on understanding the high rate of metastasis and death observed in patients diagnosed with postpartum breast cancer. They discovered a novel biology of the liver, namely that the liver undergoes tissue involution following cessation of lactation in rodents. This involution establishes a pro-metastatic environment in the liver for a period of time post-weaning that may explain the increased risk for liver metastasis observed in postpartum breast cancer patients. After this work Ejae went on to complete a postdoctoral fellowship in Dr. Cyrus Ghajar's laboratory at Fred Hutchinson Cancer Research Center. During their postdoc, Ejae studied breast cancer dormancy at metastatic sites and determined that numerous T cell-based immunotherapy platforms, including engineered T cells and T cell-based vaccine approaches, are highly effective at clearing dormant disseminated disease in rodent models. In their free time Ejae enjoys photography, rock climbing, and alpine mountaineering.

Annelise Snyder, Ph.D., is currently a postdoctoral research fellow at the Fred Hutchinson Cancer Research Center (Seattle, Washington) where she studies immune responses to metastatic breast cancer. She previously worked as a postdoctoral fellow at the Salk Institute for Biological Studies (La Jolla, California) where she conducted research related to tumor immunology and neuroimmune responses in Alzheimer's disease. Dr. Snyder holds a Ph.D. in Immunology from the University of Washington, and B.A. degrees in Biology and Chemistry from Williams College.

Brian Daniels, PhD is a faculty member and principal investigator at Rutgers University, where his laboratory pursues studies defining cellular and molecular mechanisms of neuroinflammation during viral infection and neurodegenerative disorders. He previously completed a PhD in neuroscience at Washington University in St. Louis, along with a postdoctoral fellowship in immunology at the University of Washington in Seattle.

Jack (John) McGinty, Ph.D. is a research scientist at 2seventy Bio, a biotech company making cutting-edge immunotherapies for the treatment of cancer. His current work focuses on the development of CAR T cell therapy. In this process patient T cells are isolated, genetically reprogrammed, and injected into the body where they detect and kill cancer cells. Dr. McGinty holds a Ph.D. in Immunology from the University of Washington, where he studied host immune responses to parasite infection, as well as a B.S. in Microbiology from Ohio University.

Ejae Goddard (they/them) has a background in cancer, metastasis, immunology, and T cell-based immunotherapies. They received a B.S. in Microbiology from the University of Kansas in 2004. During this time they gained experience in a research lab studying herpesviruses. They went on to earn a PhD in Cancer Research from Oregon Health and Sciences University in 2017 while working in the lab of Dr. Pepper Schedin. Ejae's PhD work focused on understanding the high rate of metastasis and death observed in patients diagnosed with postpartum breast cancer. They discovered a novel biology of the liver, namely that the liver undergoes tissue involution following cessation of lactation in rodents. This involution establishes a pro-metastatic environment in the liver for a period of time post-weaning that may explain the increased risk for liver metastasis observed in postpartum breast cancer patients. After this work Ejae went on to complete a postdoctoral fellowship in Dr. Cyrus Ghajar's laboratory at Fred Hutchinson Cancer Research Center. During their postdoc, Ejae studied breast cancer dormancy at metastatic sites and determined that numerous T cell-based immunotherapy platforms, including engineered T cells and T cell-based vaccine approaches, are highly effective at clearing dormant disseminated disease in rodent models. In their free time Ejae enjoys photography, rock climbing, and alpine mountaineering.

Annelise Snyder, Ph.D., is currently a postdoctoral research fellow at the Fred Hutchinson Cancer Research Center (Seattle, Washington) where she studies immune responses to metastatic breast cancer. She previously worked as a postdoctoral fellow at the Salk Institute for Biological Studies (La Jolla, California) where she conducted research related to tumor immunology and neuroimmune responses in Alzheimer's disease. Dr. Snyder holds a Ph.D. in Immunology from the University of Washington, and B.A. degrees in Biology and Chemistry from Williams College.

Annelise Snyder, Ph.D., is currently a postdoctoral research fellow at the Fred Hutchinson Cancer Research Center (Seattle, Washington) where she studies immune responses to metastatic breast cancer. She previously worked as a postdoctoral fellow at the Salk Institute for Biological Studies (La Jolla, California) where she conducted research related to tumor immunology and neuroimmune responses in Alzheimer's disease. Dr. Snyder holds a Ph.D. in Immunology from the University of Washington, and B.A. degrees in Biology and Chemistry from Williams College.